Blocking of C5aR in human neutrophils using the small molecule inhibitor; PMX-53, resulted in a dose-dependent block of C5a-mediated activation but why it was unsuccessful and very disappointing in RA clinical trial is unknown (275). The gene discussed is C5AR1; the disease is rheumatoid arthritis.